VIR BIOTECHNOLOGY INC (VIR)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for VIR
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| VIR | [] | ["Audit","Compensation"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ALNY | Director; Chair | 74 | ["Chief Scientific Officer of Bristol-Myers Squibb","Member of the BMS board of directors","Vice President of R&D and Chief Executive Officer for Mercator Genetics Inc.","Senior advisor to New Enterprise Associates","Co-chair of the Scientific Advisory Board for Amgen, Inc.","Director of Vir Biotechnology, Inc.","Former director of Adaptimmune Therapeutics plc","Former director of Surface Oncology Inc."] | ["People, Culture and Compensation Committee","Science and Technology Committee"] | 2026 |
| BMY | Chief Scientific Officer and President of Research and Development | 60 | ["Chief Scientific Officer since October 2004", "Executive Vice President since November 2006", "More than 25 years of combined experience in medicine, research, and management"] | ["Science and Technology", "Science and Technology Committee"] | 2012 |
Biography sourced from the proxy statement filing.
Independent Director Director Since: 2020 Age: 74 Committee Service: Compensation Science and Technology (Chair) Professional Experience: Chief Scientific Officer and President of Research & Development, Bristol-Myers Squibb Company (2004 2013), and preceded by various positions of increasing responsibility (1997 2004) President and Chief Executive Officer, Mercator Genetics Inc. (1996 1997), and previously Vice President of Research and Development (1995 1996) Education: B.S., M.S. and Ph.D., Industrial Engineering, Purdue University M.D., University of Chicago Other Public Company Boards: Alnylam Pharmaceuticals, Inc. (2022 present) Surface Oncology, Inc (2018 2023) Adaptimmune Therapeutics plc (2014 2023) Spark Therapeutics, Inc. (2014 2018) Mead Johnson Nutrition Company (2009 2017) Bristol-Myers Squibb Company (2011 2013) Other Affiliations: Service on the boards of directors for private biotechnology companies, including: Affinia Therapeutics Inc.; and Tessera Therapeutics Scientific Advisory Board, Amgen Inc. (Co-Chair) Service on faculty and research training at the Cardiovascular Research Institute at the University of California, San Francisco School of Medicine, as well as training in Internal Medicine and Pulmonary Medicine The Nominating and Corporate Governance Committee and Board believe Dr. Sigal is qualified to serve on the Board due to his extensive experience in the life sciences industry and his extensive leadership experience.